ArticleAAPS PharmSciTech2026
Effects of Different Carriers on the Stability and Pharmacokinetic Performance of Cucurbitacin B Solid Dispersions.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cucurbitacin B (CuB) is a highly oxidized tetracyclic triterpenoid classified as a Biopharmaceutics Classification System class (BCS) IV drug. Its poor solubility and low permeability significantly limit its clinical use. In an initial study, a solid dispersion formulation, CuB-PLX 407-SD, was developed and showed significantly improved dissolution rate and bioavailability. However, long-term storage led to evident crystallization and other aging-related issues, raising concerns about its stability. This study aimed to evaluate the effects of different carrier materials on the dissolution and stability of CuB solid dispersions (CuB-SD) and to assess the bioavailability of the most stable formulation. Dissolution behavior was characterized using SEM, DSC, XRPD, and FT-IR. The stability of CuB-SDs was evaluated under high-humidity storage conditions (25℃/95% RH). Relative crystallinity, and dissolution profiles were measured at scheduled intervals to identify the most stable formulation. The in vitro dissolution results indicated that all tested solid dispersions enhanced the dissolution rate of CuB. Stability analysis showed that CuB-SDs formulations using the amorphous carrier PVP VA64 and the semi-crystalline carrier PLX 407 exhibited superior stability, with PVP VA64 demonstrating the best performance. Compared to the active pharmaceutical ingredient, both CuB-PVP VA64-SD and CuB-PLX 407-SD formulations achieved substantial improvements in relative bioavailability.
Indexed as
Identifiers
42141345What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.